DR Reddys Laboratories Limited — Capecitabine Exporter Profile
Indian Pharmaceutical Exporter · #11 for Capecitabine · $650.0K export value · DGFT Verified
DR Reddys Laboratories Limited is the #11 Indian exporter of Capecitabine with $650.0K in export value and 13 verified shipments. DR Reddys Laboratories Limited holds a 0.7% market share in Capecitabine exports across 4 countries. The company exports 37 pharmaceutical products worth $62.4M across 17 therapeutic categories.
DR Reddys Laboratories Limited — Capecitabine Export Profile: Buyers & Destinations
Where Does DR Reddys Laboratories Limited Export Capecitabine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $316.4K | 7 | 61.0% |
| UNITED KINGDOM | $150.0K | 3 | 28.9% |
| AUSTRALIA | $51.9K | 2 | 10.0% |
| UZBEKISTAN | $36 | 1 | 0.0% |
DR Reddys Laboratories Limited exports Capecitabine to 4 countries. The largest destination is UNITED STATES accounting for 61.0% of DR Reddys Laboratories Limited's Capecitabine shipments, followed by UNITED KINGDOM (28.9%) and AUSTRALIA (10.0%). These destinations reflect DR Reddys Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Capecitabine from DR Reddys Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| DR REDDYS LABORATORIES INC | UNITED STATES | $266.4K | 6 |
| DR REDDY S LABORATORIES UK LTD | UNITED KINGDOM | $100.0K | 2 |
| DR REDDY S LABORATORIES INC | UNITED STATES | $50.0K | 1 |
| DR REDDYS S LABORATORIES U K LIMITED | UNITED KINGDOM | $50.0K | 1 |
| DR REDDY S LABORATORIES AUSTRALIA PTY LTD | AUSTRALIA | $45.6K | 1 |
| DR REDDY S LABORATORIES AUSTRALIA P L | AUSTRALIA | $6.4K | 1 |
| STATE CENTRE OF EXPERTIZE AND | UZBEKISTAN | $36 | 1 |
DR Reddys Laboratories Limited supplies Capecitabine to 7 buyers globally. The largest buyer is DR REDDYS LABORATORIES INC (UNITED STATES), followed by DR REDDY S LABORATORIES UK LTD (UNITED KINGDOM) and DR REDDY S LABORATORIES INC (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Capecitabine Export Value and How Much Does DR Reddys Laboratories Limited Contribute?
India exported $32.0M worth of Capecitabine through 2,246 shipments from 216 suppliers to 123 countries, serving 516 buyers globally. DR Reddys Laboratories Limited contributes $650.0K to this total, accounting for 0.7% of India's Capecitabine exports. DR Reddys Laboratories Limited ships Capecitabine to 4 countries through 7 buyers.
What Is the Average Shipment Value for DR Reddys Laboratories Limited's Capecitabine Exports?
DR Reddys Laboratories Limited's average Capecitabine shipment value is $50.0K per consignment, based on 13 shipments totaling $650.0K. The largest destination is UNITED STATES (61.0% of DR Reddys Laboratories Limited's Capecitabine exports).
How Does DR Reddys Laboratories Limited Compare to Other Indian Capecitabine Exporters?
DR Reddys Laboratories Limited ranks #11 among 216 Indian Capecitabine exporters with a 0.7% market share. The top 3 exporters are MSN LABORATORIES PRIVATE LIMITED ($7.4M), INTAS PHARMACEUTICALS LIMITED ($5.0M), EUGIA PHARMA SPECIALITIES LIMITED ($4.0M). DR Reddys Laboratories Limited processed 13 shipments to 4 destination countries.
What Capecitabine Formulations Does DR Reddys Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CAPECITABINE TABS USP 500 MG 120'S USA | $200.0K | 4 |
| CAPECITABINE TABS USP 150 MG 60'S USA | $116.4K | 3 |
| CAPECITABINE FC TAB 500MG 120S12X10SUK | $100.0K | 2 |
| CAPECITABINE FC TAB 500MG 120S | $50.0K | 1 |
| CAPECITABINE-DRLA 500 FCTAB 120 AUS | $45.6K | 1 |
| CAPECITABINE-DRLA 150 FCTAB 60 AUS | $6.4K | 1 |
| CAPECITABINE TABLETS USP 500 MG KAPFURO | $36 | 1 |
DR Reddys Laboratories Limited exports 7 distinct Capecitabine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CAPECITABINE TABS USP 500 MG 120'S USA with 4 shipments worth $200.0K.
Regulatory Requirements: Exporting Capecitabine to Key Markets
What DR Reddys Laboratories Limited must comply with to export Capecitabine to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does DR Reddys Laboratories Limited Compare to Nearest Capecitabine Exporters?
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 10 | NAPROD LIFE SCIENCES PRIVATE LIMITED | $946.4K | 27 | 5 | $35.1K |
| 12 | BETA DRUGS LIMITED | $708.5K | 124 | 12 | $5.7K |
| 11 | DR REDDYS LABORATORIES LIMITED ★ | $650.0K | 13 | 4 | $50.0K |
| 13 | BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED | $599.5K | 17 | 3 | $35.3K |
| 14 | CIPLA LIMITED | $596.3K | 18 | 4 | $33.1K |
DR Reddys Laboratories Limited ranks #11 among 216 Indian Capecitabine exporters. Average shipment value of $50.0K compared to the market average of $148.1K. The closest competitors by value are NAPROD LIFE SCIENCES PRIVATE LIMITED and BETA DRUGS LIMITED.
Which Indian Ports Ship Capecitabine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 359 | 16.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 283 | 12.6% |
| DELHI AIR CARGO ACC (INDEL4) | 233 | 10.4% |
| HYDERABAD ICD (INSNF6) | 173 | 7.7% |
| HYDERABAD AIR | 154 | 6.9% |
| DELHI AIR | 142 | 6.3% |
| HYDERABAD ACC (INHYD4) | 89 | 4.0% |
| Bombay Air | 80 | 3.6% |
What Other Advanced Oncology Products Does DR Reddys Laboratories Limited Export?
DR Reddys Laboratories Limited also exports these advanced oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on DR Reddys Laboratories Limited's Capecitabine Exports
The global pharmaceutical export landscape has been significantly influenced by recent geopolitical events. The 2026 Strait of Hormuz crisis, initiated by military conflicts involving the United States, Israel, and Iran, led to the effective halt of shipping traffic through this critical maritime route, disrupting approximately 20% of the world's daily oil supply and causing a surge in global energy prices. (en.wikipedia.org) This disruption has had a cascading effect on shipping costs and insurance premiums, directly impacting Indian pharmaceutical exporters like Dr. Reddy's, which rely on these routes for timely delivery of products to key markets.
Simultaneously, the 2025–26 United States–India diplomatic and trade crisis, marked by the imposition of a 50% tariff on Indian exports by the U.S., has posed additional challenges. These tariffs have increased the cost of Indian pharmaceutical products in the U.S. market, potentially affecting the competitiveness of companies like Dr. Reddy's. (en.wikipedia.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. Dr. Reddy's has been proactive in adhering to these regulations, ensuring that its products meet the stringent safety and traceability standards mandated by the EU, thereby maintaining its market access and reputation.
DR Reddys Laboratories Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. Dr. Reddy's has demonstrated a commitment to quality by securing approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Medicines Agency (EMA). The company's recent Biologics License Application (BLA) submission for a proposed interchangeable biosimilar to Orencia® (abatacept) underscores its adherence to rigorous regulatory processes. (stockwatch.com)
However, the company has faced regulatory challenges, such as the tax audit decision from the Russian Federal Tax Service in January 2026, which reclassified certain marketing services as taxable, resulting in a penalty. (stocktitan.net) Such incidents highlight the complexities of operating in diverse regulatory environments and the importance of robust compliance frameworks.
About DR Reddys Laboratories Limited
DR Reddys Laboratories Limited exports 37 products worth $62.4M. Beyond Capecitabine, top products include Omeprazole, Metoprolol, Diclofenac, Clopidogrel, Fexofenadine. View the complete DR Reddys Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Capecitabine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Capecitabine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: DR Reddys Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 13 individual customs records matching DR Reddys Laboratories Limited exporting Capecitabine, covering 7 formulations to 4 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 123+ countries, 516+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Capecitabine Export Data from DR Reddys Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for DR Reddys Laboratories Limited's Capecitabine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
DR Reddys Laboratories Limited
Full Company Profile →
37 products · $62.4M total trade · 17 categories
Capecitabine Stats
Company Overview
Top Products by DR Reddys Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for DR Reddys Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Capecitabine. For current shipment-level data, contact TransData Nexus.